A Two Part, Open-label Study to Evaluate the Safety and Effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 Given With or Without a Drug Called Ribavirin in People With Both Hepatitis C Virus Genotype 1 or 4 Infection and Human Immunodeficiency Virus, Type 1 Infection (TURQUOISE-I)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2015 by AbbVie
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: September 6, 2013
Last updated: October 3, 2015
Last verified: October 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2016
  Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
No publications provided by AbbVie

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):